Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
2001-01-23
2004-12-21
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
active
06833365
ABSTRACT:
BACKGROUND OF THE INVENTION
Cryptosporidium parvum
(or
C. parvum
) is an enteric protozoa of the phylum Apicomplexa. It is a major cause of diarrhea in humans and certain domestic animals (Tzipori,
Advances in Parasitology
(1988) 27:63-129). It is responsible for sporadic cases and major waterborne outbreaks of self-limiting diarrhea in immunocompetent humans (Current, W. L. et al.,
Clinical Microbiology Reviews
, (1991) 4:325).
C. parvum
is one of several important opportunistic infections (OI) associated with diarrhea and wasting in patients with AIDS. Depending on location in the United States, some 10 to 15% of individuals with AIDS contract the disease (Peterson,
Clinical Infectious Diseases
, (1992) 15:903). The infection in the immunodeficient host often becomes persistent, causing life-threatening, profound, unremitting watery diarrhea and wasting. A prolonged course of infection often leads to a spread of infection into the hepatobiliary (HB) tract causing serious complications (Flanigan,
Progress in Clinical Parasitiology
(1993) 3:1). Of the OI affecting patients with AIDS,
C. parvum
is one of only a few infections against which there is no consistently effective treatment. There had been only a few reports of successful treatment of individual AIDS patients with hyperimmune bovine colostrum (Tzipori,
Lancet
. (1986) ii:344; Ungar,
Gastroenterology
(1990) 98:486) and with paromomycin (PRM) (Fitchenbaum,
Clinical Infectious Diseases
(1993) 16:298). Since none of the available antimicrobial agents are consistently effective, a search for novel therapeutic agents against
C. parvum
is necessary. With increased survival time of patients with AIDS due to much improved patient care, the incidence of the disease in this population is likely to continue to rise.
The lifecycle of
C. parvum
is similar to that of other coccidia which infect mammals. The lifecycle can be divided into six major developmental events (Current,
Journal of Protozoology
, (1986) 33:98); excystation, the release of infective sporozoites; merogony, the asexual multiplication within host cells; gametogony, the formation of micro and macrogametes; fertilization, the union of micro and macrogametes; oocyst wall formation, to produce an environmentally resistant stage that transmits infection from one host to another; and sporogony, the formation of infective sporozoites within the oocyst wall. Each intracellular stage of
C. parvum
resides within a parasitophorous vacuole confined to the microvillous region of the host cell, whereas comparable stages of
Toxoplasma gondii, Eimeria
, or
Isopora
to which
C. parvum
is closely related, occupy parasitophorous vacuoles deep within the host cytoplasm. Oocysts of
C. parvum
undergo sporogony while they are within the host cells and are infective when released in the feces. Approximately 20% of the oocysts of
C. parvum
are thin walled and discharge their sporozoites within the lumen of the same host, while 80% form a thick two-layered environmentally resistant oocyst wall, and are discharged in the feces. The four sporozoites emerging from the thin-walled oocysts and repeated cycles of schizogeny contribute to the persistence of the infection in the immunodeficient host known as autoinfection.
SUMMARY OF THE INVENTION
In one embodiment, the invention pertains to a method for controlling
Cryptosporidium parvum
in a mammal, by administering to the mammal an effective amount of a tetracycline compound. Examples of tetracycline compounds of the invention include compounds of formula I:
wherein:
X is CHC(R
13
Y′Y), CHR
6
, S, NR
6
, or O;
R
2
, R
4
and R
4′
are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
R
2′
, R
3
, R
10
, R
11
and R
12
are each hydrogen or a pro-drug moiety;
R
5
is hydroxy, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R
6
, R
7
, R
8
and R
9
are each independently hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R
13
is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
Y′ and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
and pharmaceutically acceptable salts thereof.
The invention also pertains to a method for treating a
Cryptosporidium parvum
related disorder in a mammal, by administering to the mammal an effective amount of a tetracycline compound. In an embodiment, the tetracycline compound is of formula (I). In another advantageous embodiment, the mammal is immunocompromised, e.g., suffering from AIDS or undergoing chemotherapy. Preferably, the mammal is a human.
In another embodiment, the invention pertains to pharmaceutical compositions containing an effective amount of a tetracycline compound to treat a
Cryptosporidium parvum
related disorder in a mammal and a pharmaceutically acceptable carrier.
In yet another embodiment, the invention features a tetracycline compound of the formula:
REFERENCES:
patent: 2980584 (1961-04-01), Hammer
patent: 2990331 (1961-06-01), Neumann et al.
patent: 3062717 (1962-11-01), Hammer
patent: 3165531 (1965-01-01), Blackwood et al.
patent: 3454697 (1969-07-01), Joyner et al.
patent: 3557280 (1971-01-01), Weber et al.
patent: 3674859 (1972-07-01), Beutel et al.
patent: 3957980 (1976-05-01), Noseworthy
patent: 4018889 (1977-04-01), Armstrong
patent: 4024272 (1977-05-01), Rogalski et al.
patent: 4126680 (1978-11-01), Armstrong
patent: 5532227 (1996-07-01), Golub et al.
patent: 5639742 (1997-06-01), Lee et al.
patent: 5789395 (1998-08-01), Amin et al.
patent: 5834450 (1998-11-01), Su
patent: WO 9308806 (1993-05-01), None
patent: WO 9937306 (1999-07-01), None
Armson et al., “Assessment of drugs againstCryptospordium parvumusing a simple in vitro screening method.” FEMS Microbiology Letters, vol. 178, pp. 227-233, 1999.*
Armson A., et al. “Assessment of drugs againstCryptosporidium parvumusing a simple in vitro screening metho,”FEMS Microbiol Lett.Sep. 15, 1999;178(2):227-33.
Brites C., et al. “Multiple drug regimen for severe diarrhea associated withCryptosporidiumin AIDS patients,”Rev Soc Bras Med Trop.Apr.-Jun. 1991;24(2):117.
Current, W.L. et al., “A comparison of endogenous development of three isolates ofcryptosporidiumin suckling mice,”J. Protozoology33:98-108 (1986).
Current, W.L. et al., “Cryptosporidiosis,”Clin Microbiol. Rev.4(3):325-358 (1991).
Fayer, R., et al., “Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptoporidiosis in neonatal BALB/c mice,”J Parasitol.Aug. 1993;79(4):553-8.
Fitchenbaum, C.J. et al., “Use of paromomycin for treatment of cryptosporidiosis in patients with aids,”Clinical Infectious Diseases16:298 (1993).
Flanigan T.P., et al. “Cryptosporidia,”Prog. Clin Parasitol.3:1 (1993).
Keusch, G.T. et al., “Cryptosporidia—Who is at risk?,”Schweiz Med Wochenschr.125(18):899-908 (1995).
Nelson, M.L. et al., “Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines,”J. Med. Chem.36(3):370-377 (1993).
Peterson, C., “Cryptosporidiosis in patients infected with the human immunodeficiencyvirus,”Clin. Infec. Dis.15:903 (1992).
Tzipori, S. et al. “Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum,”Lancet2(8554):344 (1987).
Tzipori, S., “Cryptosporidiosis in perspective,”Advances in Parasitology27:63-129 (1988).
Ungar, B.L.P. et al., “Cessation ofcryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum,”Gastroenterology98:486-489 (1990).
Levy Stuart B.
Nelson Mark L.
Badio Barbara P.
Hanley, Esq. Elizabeth A.
Lahive & Cockfield LLP
Soroos, Esq. Cynthia M.
Trustees of Tufts College
LandOfFree
Tetracycline compounds for treatment of Cryptosporidium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetracycline compounds for treatment of Cryptosporidium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetracycline compounds for treatment of Cryptosporidium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3336062